The loss of SGLT2 function induced by SNA-modified SGLT2-ASOs was verified by the appearance of glucosuria, which is similar to the effect exerted by SGLT2 inhibitors used in clinical practice.20 This evidence concerns the gene SLC5A2 and Glycosuria.